Development and Challenges of Cyclic Peptides for Immunomodulation

Muttenthaler, M.; King, G.F.; Adams, D.J.; Alewood, P.F. Trends in peptide drug discovery. Nat. Rev. Drug Discov., 2021, 20(4), 309-325.
[http://dx.doi.org/10.1038/s41573-020-00135-8] [PMID: 33536635]

Abdalla, M.; McGaw, L. Natural cyclic peptides as an attractive modality for therapeutics: A mini review. Molecules, 2018, 23(8), 2080-2198.
[http://dx.doi.org/10.3390/molecules23082080] [PMID: 30127265]

Bellavita, R.; Maione, A.; Merlino, F.; Siciliano, A.; Dardano, P.; De Stefano, L.; Galdiero, S.; Galdiero, E.; Grieco, P.; Falanga, A. Antifungal and antibiofilm activity of cyclic temporin L peptide analogues against albicans and non-albicans candida species. Pharmaceutics, 2022, 14(2), 454-478.
[http://dx.doi.org/10.3390/pharmaceutics14020454] [PMID: 35214187]

(a) Bajraktari-Sylejmani, G.; Von Linde, T.; Burhenne, J.; Haefeli, W.E.; Sauter, M.; Weiss, J. Evaluation of pept1 (slC15A1) substrate characteristics of therapeutic cyclic peptides. Pharmaceutics, 2022, 14(8), 1610-1620.
[http://dx.doi.org/10.3390/pharmaceutics14081610] [PMID: 36015235];
(b) Horton, D.A.; Bourne, G.T.; Smythe, M.L. Exploring privileged structures: the combinatorial synthesis of cyclic peptides. J. Comput. Aided Mol. Des., 2002, 16(5/6), 415-431.
[http://dx.doi.org/10.1023/A:1020863921840] [PMID: 12489688];
(c) Furman, O.; Zaporozhets, A.; Tobi, D.; Bazylevich, A.; Firer, M.A.; Patsenker, L.; Gellerman, G.; Lubin, B.C.R. Novel cyclic peptides for targeting EGFR and EGRvIII mutation for drug delivery. Pharmaceutics, 2022, 14(7), 1505-1522.
[http://dx.doi.org/10.3390/pharmaceutics14071505] [PMID: 35890400];
(d) Gallo, M.; Defaus, S.; Andreu, D. Disrupting GPCR complexes with smart drug-like peptides. Pharmaceutics, 2022, 14(1), 161-177.
[http://dx.doi.org/10.3390/pharmaceutics14010161] [PMID: 35057055]

Yang, L.; Tan, R.; Wang, Q.; Huang, W.; Yin, Y. Antifungal cyclopeptides from halobacillus litoralis ys3106 of marine origin. Tetrahedron Lett., 2002, 43(37), 6545-6548.
[http://dx.doi.org/10.1016/S0040-4039(02)01458-2]

Jiang, L.; Huang, P.; Ren, B.; Song, Z.; Zhu, G.; He, W.; Zhang, J.; Oyeleye, A.; Dai, H.; Zhang, L.; Liu, X. Antibacterial polyene-polyol macrolides and cyclic peptides from the marine-derived Streptomyces sp. MS110128. Appl. Microbiol. Biotechnol., 2021, 105(12), 4975-4986.
[http://dx.doi.org/10.1007/s00253-021-11226-w] [PMID: 34146138]

Karim, M.R.U.; In, Y.; Zhou, T.; Harunari, E.; Oku, N.; Igarashi, Y. Nyuzenamides A and B: Bicyclic peptides with antifungal and cytotoxic activity from a marine-derived streptomyces sp. Org. Lett., 2021, 23(6), 2109-2113.
[http://dx.doi.org/10.1021/acs.orglett.1c00210] [PMID: 33661652]

Muratspahić, E.; Tomašević, N.; Nasrollahi-Shirazi, S.; Gattringer, J.; Emser, F.S.; Freissmuth, M.; Gruber, C.W. Plant-Derived cyclotides modulate κ-opioid receptor signaling. J. Nat. Prod., 2021, 84(8), 2238-2248.
[http://dx.doi.org/10.1021/acs.jnatprod.1c00301] [PMID: 34308635]

(a) Du, Q.; Huang, Y.H.; Bajpai, A.; Frosig- Jorgensen, M.; Zhao, G.; Craik, D.J. Evaluation of the in vivo Aphrodisiac Activity of a Cyclotide Extract from Hybanthus enneaspermus. J. Nat. Prod., 2020, 83(12), 3736-3743.
[http://dx.doi.org/10.1021/acs.jnatprod.0c01045] [PMID: 33296204];
(b) Fahradpour, M.; Keov, P.; Tognola, C.; Perez-Santamarina, E.; McCormick, P.J.; Ghassempour, A.; Gruber, C.W. Cyclotides isolated from an ipecac root extract antagonize the corticotropin releasing factor type 1 receptor. Front. Pharmacol., 2017, 8, 616-629.
[http://dx.doi.org/10.3389/fphar.2017.00616] [PMID: 29033832];
(c) Anastasiou, E.; Lorentz, K.O.; Stein, G.J.; Mitchell, P.D. Prehistoric schistosomiasis parasite found in the middle east. Lancet Infect. Dis., 2014, 14(7), 553-554.
[http://dx.doi.org/10.1016/S1473-3099(14)70794-7] [PMID: 24953264]

Abdalla, M.A. Three new cyclotetrapeptides isolated from streptomyces sp. 447. Nat. Prod. Res., 2017, 31(9), 1014-1021.
[http://dx.doi.org/10.1080/14786419.2016.1263849] [PMID: 27936924]

Wyche, T.P.; Ruzzini, A.C.; Schwab, L.; Currie, C.R.; Clardy, J.; Tryptorubin, A. Tryptorubin A: A polycyclic peptide from a fungus-derived streptomycete. J. Am. Chem. Soc., 2017, 139(37), 12899-12902.
[http://dx.doi.org/10.1021/jacs.7b06176] [PMID: 28853867]

Liang, X.; Nong, X.H.; Huang, Z.H.; Qi, S.H. Antifungal and antiviral cyclic peptides from the deep-sea-derived fungus simplicillium obclavatum EIODSF 020. J. Agric. Food Chem., 2017, 65(25), 5114-5121.
[http://dx.doi.org/10.1021/acs.jafc.7b01238] [PMID: 28578573]

Zhou, T.; Katsuragawa, M.; Xing, T.; Fukaya, K.; Okuda, T.; Tokiwa, T.; Tashiro, E.; Imoto, M.; Oku, N.; Urabe, D.; Igarashi, Y. Cyclopeptides from the mushroom pathogen fungus cladobotryum varium. J. Nat. Prod., 2021, 84(2), 327-338.
[http://dx.doi.org/10.1021/acs.jnatprod.0c00980] [PMID: 33439652]

Takashina, K.; Katsuyama, A.; Kaguchi, R.; Yamamoto, K.; Sato, T.; Takahashi, S.; Horiuchi, M.; Yokota, S.; Ichikawa, S. Solid-phase total synthesis of plusbacin A₃. Org. Lett., 2022, 24(11), 2253-2257.
[http://dx.doi.org/10.1021/acs.orglett.2c00667] [PMID: 35293208]

Ullrich, S.; George, J.; Coram, A.E.; Morewood, R.; Nitsche, C. Biocompatible and selective generation of bicyclic peptides. Angew. Chem. Int. Ed., 2022, 61(43), e202208400.
[http://dx.doi.org/10.1002/anie.202208400] [PMID: 35852030]

Marciniak, A.; Pacini, L.; Papini, A.M.; Brasuń, J. Bicyclopeptides: a new class of ligands for Cu( II ) ions. Dalton Trans., 2022, 51(35), 13368-13375.
[http://dx.doi.org/10.1039/D2DT01497A] [PMID: 35984441]

Yates, N.D.J.; Warnes, M.E.; Breetveld, R.; Spicer, C.D.; Signoret, N.; Fascione, M. Preparation and application of an inexpensive α-formylglycine building block compatible with fmoc solid-phase peptide synthesis. Org. Lett., 2023, 25(12), 2001-2005.
[http://dx.doi.org/10.1021/acs.orglett.2c04059] [PMID: 36662590]

Nagaya, A.; Murase, S.; Mimori, Y.; Wakui, K.; Yoshino, M.; Matsuda, A.; Kobayashi, Y.; Kurasaki, H.; Cary, D.R.; Masuya, K.; Handa, M.; Nishizawa, N. Extended solution-phase peptide synthesis strategy using isostearyl-mixed anhydride coupling and a new C-terminal silyl ester-protecting group for N -methylated cyclic peptide production. Org. Process Res. Dev., 2021, 25(9), 2029-2038.
[http://dx.doi.org/10.1021/acs.oprd.1c00078]

Li, H.; Li, J.; Chao, J.; Zhang, Z.; Qin, C. Total liquid-phase sythesis, head-to-tail cyclization and synergistic self-cleavage of peptide on small-molecular supports. ChemRxiv, 2021, 2021

Hossain, F.; Nishat, S.; Andreana, P.R. Synthesis of malformin-A ₁, C, a glycan, and an aglycon analog: Potential scaffolds for targeted cancer therapy. Pept. Sci., 2022, 114(4), e24260.
[http://dx.doi.org/10.1002/pep2.24260]

Kanwal, I.; Mushtaq, F.; Ali, H.; Tufail, P.; Jahan, H.; Shaheen, F. First report on the synthesis and structural studies of trans-Phakellistatin 18: A rotamer of marine natural product phakellistatin 18. Nat. Prod. Res., 2023, 37(9), 1470-1479.
[http://dx.doi.org/10.1080/14786419.2021.2023141] [PMID: 34986732]

Yayat, H.N.A.; Maharani, R.; Hidayat, A.T.; Wiani, I.; Zainuddin, A.; Mayanti, T.; Nurlelasari; Harneti, D.; Supratman, U. Total synthesis of a reversed cyclopurpuracin using a combination of solid and solution phase methods. J. Heterocycl. Chem., 2022, 59(11), 1963-1970.
[http://dx.doi.org/10.1002/jhet.4532]

Napitupulu, O.I.; Sumiarsa, D.; Subroto, T.; Nurlelasari; Harneti, D.; Supratman, U.; Maharani, R. Synthesis of cyclo-PLAI using a combination of solid- and solution-phase methods. Synth. Commun., 2019, 49(2), 308-315.
[http://dx.doi.org/10.1080/00397911.2018.1554148]

Wills, R.; Adebomi, V.; Raj, M. Site-selective peptide macrocyclization. ChemBioChem, 2021, 22(1), 52-62.
[http://dx.doi.org/10.1002/cbic.202000398] [PMID: 32794268]

Raj, M.; Wills, R.D.; Adebomi, V.T. Peptide cyclization at high concentration. Synlett, 2020, 31(16), 1537-1542.
[http://dx.doi.org/10.1055/s-0040-1707165]

Wills, R.; Adebomi, V.; Spancake, C.; Cohen, R.D.; Raj, M. Synthesis of L-cyclic tetrapeptides by backbone amide activation CyClick strategy. Tetrahedron, 2022, 126, 133071-133076.
[http://dx.doi.org/10.1016/j.tet.2022.133071]

Habibi, Y.; Weerasinghe, N.W.; Uggowitzer, K.A.; Thibodeaux, C.J. Partially modified peptide intermediates in lanthipeptide biosynthesis alter the structure and dynamics of a lanthipeptide synthetase. J. Am. Chem. Soc., 2022, 144(23), 10230-10240.
[http://dx.doi.org/10.1021/jacs.2c00727] [PMID: 35647706]

(a) Rice, A.J.; Pelton, J.M.; Kramer, N.J.; Catlin, D.S.; Nair, S.K.; Pogorelov, T.V.; Mitchell, D.A.; Bowers, A.A. Enzymatic pyridine aromatization during thiopeptide biosynthesis. J. Am. Chem. Soc., 2022, 144(46), 21116-21124.
[http://dx.doi.org/10.1021/jacs.2c07377] [PMID: 36351243];
(b) Nguyen, D.T.; Le, T.T.; Rice, A.J.; Hudson, G.A.; Van der Donk, W.A.; Mitchell, D.A. Accessing diverse pyridine-based macrocyclic peptides by a two-site recognition pathway. J. Am. Chem. Soc., 2022, 144(25), 11263-11269.
[http://dx.doi.org/10.1021/jacs.2c02824] [PMID: 35713415]

Kersten, R.D.; Mydy, L.S.; Fallon, T.R.; de Waal, F.; Shafiq, K.; Wotring, J.W.; Sexton, J.Z.; Weng, J.K. Gene-guided discovery and ribosomal biosynthesis of moroidin peptides. J. Am. Chem. Soc., 2022, 144(17), 7686-7692.
[http://dx.doi.org/10.1021/jacs.2c00014] [PMID: 35438481]

Sugiyama, R.; Suarez, A.F.L.; Morishita, Y.; Nguyen, T.Q.N.; Tooh, Y.W.; Roslan, M.N.H.B.; Lo Choy, J.; Su, Q.; Goh, W.Y.; Gunawan, G.A.; Wong, F.T.; Morinaka, B.I. The biosynthetic landscape of triceptides reveals radical sam enzymes that catalyze cyclophane formation on tyr- and his-containing motifs. J. Am. Chem. Soc., 2022, 144(26), 11580-11593.
[http://dx.doi.org/10.1021/jacs.2c00521] [PMID: 35729768]

Luo, J.; Liu, S.; Lu, H.; Chen, Q.; Shi, Y. A comprehensive review of microorganism-derived cyclic peptides: Bioactive functions and food safety applications. Compr. Rev. Food Sci. Food Saf., 2022, 21(6), 5272-5290.
[http://dx.doi.org/10.1111/1541-4337.13038] [PMID: 36161470]

Kazmaier, U.; Junk, L. Recent developments on the synthesis and bioactivity of ilamycins/rufomycins and cyclomarins, marine cyclopeptides that demonstrate anti-malaria and anti-tuberculosis activity. Mar. Drugs, 2021, 19(8), 446-472.
[http://dx.doi.org/10.3390/md19080446] [PMID: 34436284]

Kazemi Shariat Panahi, H.; Mohammadipanah, F.; Rahmati, F.; Tarlani, A.; Hamedi, J. In situ recovery of persipeptides from streptomyces zagrosensis fermentation broth by enhanced adsorption. Iran. J. Biotechnol., 2020, 18(2), e2231-e2240.
[PMID: 33542931]

Helaly, S.E.; Hamad, Z.; El Sayed, M.A.; Abdel-Motaal, F.F.; Nassar, M.I.; Ito, S.; Stadler, M. Bacillus methylotrophicus ASWU-C2, a strain inhabiting hot desert soil, a new source for antibacterial bacillopyrone, pyrophen, and cyclopeptides. Z. Naturforsch. C J. Biosci., 2018, 74(1-2), 55-59.
[http://dx.doi.org/10.1515/znc-2018-0093] [PMID: 30864389]

(a) Zhao, L.; Wei, L.; Li, X.; Chen, H.; Liu, J.; Wang, X.; Guan, F. Design and synthesis of novel cyclopeptide p53-MDM2 inhibitors with isoindolinone as antitumor agent. J. Mol. Struct., 2023, 1275, 134604-134610.
[http://dx.doi.org/10.1016/j.molstruc.2022.134604];
(b) Xiao, S.; Wang, Z.; Zhang, H.; Zhao, L.; Chang, Q.; Zhang, X.; Yan, R.; Wu, X.; Jin, Y. Photoinduced synthesis of methylated marine cyclopeptide galaxamide analogs with isoindolinone as anticancer agents. Mar. Drugs, 2022, 20(6), 379-399.
[http://dx.doi.org/10.3390/md20060379] [PMID: 35736182];
(c) Jiang, S.; Zhao, L.; Wu, J.; Bao, Y.; Wang, Z.; Jin, Y. Photo-induced synthesis, structure and in vitro bioactivity of a natural cyclic peptide Yunnanin A analog. RSC Advances, 2020, 10(1), 210-214.
[http://dx.doi.org/10.1039/C9RA09163G] [PMID: 35492554];
(d) Zhang, H.; Wu, J.; Wang, J.; Xiao, S.; Zhao, L.; Yan, R.; Wu, X.; Wang, Z.; Fan, L.; Jin, Y. Novel Isoindolinone-based analogs of the natural cyclic peptide fenestin A: Synthesis and antitumor activity. ACS Med. Chem. Lett., 2022, 13(7), 1118-1124.
[http://dx.doi.org/10.1021/acsmedchemlett.2c00149] [PMID: 35859879];
(e) Bao, Y.; Zhao, L.; Wu, J.; Jiang, S.; Wang, Z.; Jin, Y. Photo-induced synthesis of Axinastatin 3 analogs, the secondary structures and their in vitro antitumor activities. Bioorg. Med. Chem. Lett., 2019, 29(22), 126730-126734.
[http://dx.doi.org/10.1016/j.bmcl.2019.126730] [PMID: 31607609]

(a) Zhang, J.N.; Xia, Y.X.; Zhang, H.J. Natural cyclopeptides as anticancer agents in the last 20 years. Int. J. Mol. Sci., 2021, 22(8), 3973-4030.
[http://dx.doi.org/10.3390/ijms22083973] [PMID: 33921480];
(b) Zhao, K.; Xing, R.; Yan, X. Cyclic dipeptides: Biological activities and self-assembled materials. Pept. Sci., 2021, 113(2), e24202-e24214.
[http://dx.doi.org/10.1002/pep2.24202];
(c) Jwad, R.; Weissberger, D.; Hunter, L. Strategies for fine-tuning the conformations of cyclic peptides. Chem. Rev., 2020, 120(17), 9743-9789.
[http://dx.doi.org/10.1021/acs.chemrev.0c00013] [PMID: 32786420];
(d) Chow, H.Y.; Zhang, Y.; Matheson, E.; Li, X. Ligation technologies for the synthesis of cyclic peptides. Chem. Rev., 2019, 119(17), 9971-10001.
[http://dx.doi.org/10.1021/acs.chemrev.8b00657] [PMID: 31318534];
(e) Malde, A.K.; Hill, T.A.; Iyer, A.; Fairlie, D.P. Crystal structures of protein-bound cyclic peptides. Chem. Rev., 2019, 119(17), 9861-9914.
[http://dx.doi.org/10.1021/acs.chemrev.8b00807] [PMID: 31046237];
(f) Nielsen, D.S.; Shepherd, N.E.; Xu, W.; Lucke, A.J.; Stoermer, M.J.; Fairlie, D.P. Orally absorbed cyclic peptides. Chem. Rev., 2017, 117(12), 8094-8128.
[http://dx.doi.org/10.1021/acs.chemrev.6b00838] [PMID: 28541045];
(g) Dougherty, P.G.; Sahni, A.; Pei, D. Understanding cell penetration of cyclic peptides. Chem. Rev., 2019, 119(17), 10241-10287.
[http://dx.doi.org/10.1021/acs.chemrev.9b00008] [PMID: 31083977];
(h) Zorzi, A.; Deyle, K.; Heinis, C. Cyclic peptide therapeutics: Past, present and future. Curr. Opin. Chem. Biol., 2017, 38, 24-29.
[http://dx.doi.org/10.1016/j.cbpa.2017.02.006] [PMID: 28249193]

Räder, A.F.B.; Reichart, F.; Weinmüller, M.; Kessler, H. Improving oral bioavailability of cyclic peptides by N-methylation. Bioorg. Med. Chem., 2018, 26(10), 2766-2773.
[http://dx.doi.org/10.1016/j.bmc.2017.08.031] [PMID: 28886995]

Iskandarsyah; Tejo, B.A.; Tambunan, U.S.F.; Verkhivker, G.; Siahaan, T.J. Structural modifications of ICAM-1 cyclic peptides to improve the activity to inhibit heterotypic adhesion of T cells. Chem. Biol. Drug Des., 2008, 72(1), 27-33.
[http://dx.doi.org/10.1111/j.1747-0285.2008.00676.x] [PMID: 18554252]

Tang, J.; He, Y.; Chen, H.; Sheng, W.; Wang, H. Synthesis of bioactive and stabilized cyclic peptides by macrocyclization using C(sp³)–H activation. Chem. Sci., 2017, 8(6), 4565-4570.
[http://dx.doi.org/10.1039/C6SC05530C] [PMID: 28936334]

Ulapane, K.R.; Kopec, B.M.; Siahaan, T.J. Improving in vivo brain delivery of monoclonal antibody using novel cyclic peptides. Pharmaceutics, 2019, 11(11), 568-582.
[http://dx.doi.org/10.3390/pharmaceutics11110568] [PMID: 31683745]

Kumar, S.; Mandal, D.; El-Mowafi, S.A.; Mozaffari, S.; Tiwari, R.K.; Parang, K. Click-free synthesis of a multivalent tricyclic peptide as a molecular transporter. Pharmaceutics, 2020, 12(9), 842-858.
[http://dx.doi.org/10.3390/pharmaceutics12090842] [PMID: 32899170]

Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 1997, 23(1-3), 3-25.

Wang, H.M.; Seo, C.D.; Lee, K.J.; Park, J.H.; Lim, H.S. Evaluation of the cell permeability of bicyclic peptoids and bicyclic peptide-peptoid hybrids. Bioorg. Chem., 2022, 127, 105976-105983.
[http://dx.doi.org/10.1016/j.bioorg.2022.105976] [PMID: 35777233]

Riniker, S.; Zurich, E. Toward the elucidation of the mechanism for passive membrane permeability of cyclic peptides. Future Med. Chem., 2019, 11(7), 637-639.
[http://dx.doi.org/10.4155/fmc-2018-0429] [PMID: 30920310]

Linker, S.M.; Schellhaas, C.; Ries, B.; Roth, H.J.; Fouché, M.; Rodde, S.; Riniker, S. Polar/apolar interfaces modulate the conformational behavior of cyclic peptides with impact on their passive membrane permeability. RSC Advances, 2022, 12(10), 5782-5796.
[http://dx.doi.org/10.1039/D1RA09025A] [PMID: 35424539]

Ono, T.; Tabata, K.V.; Goto, Y.; Saito, Y.; Suga, H.; Noji, H.; Morimoto, J.; Sando, S. Label-free quantification of passive membrane permeability of cyclic peptides across lipid bilayers: Penetration speed of cyclosporin A across lipid bilayers. Chem. Sci., 2023, 14(2), 345-349.
[http://dx.doi.org/10.1039/D2SC05785A] [PMID: 36687349]

Peraro, L.; Kritzer, J.A. Emerging methods and design principles for cell-penetrant peptides. Angew. Chem. Int. Ed., 2018, 57(37), 11868-11881.
[http://dx.doi.org/10.1002/anie.201801361] [PMID: 29740917]

Salim, H.; Pei, D. Assessing the cellular uptake, endosomal escape, and cytosolic entry efficiencies of cyclic peptides. Methods Mol. Biol., 2022, 2371(16), 301-316.
[http://dx.doi.org/10.1007/978-1-0716-1689-5_16] [PMID: 34596855]

Levi, B.; Yacobovich, S.; Kirby, M.; Becker, M.; Agranyoni, O.; Redko, B.; Gellerman, G.; Pinhasov, A.; Koman, I.; Nesher, E. Anti-cancer effects of cyclic peptide ALOS4 in a human melanoma mouse model. Int. J. Mol. Sci., 2021, 22(17), 9579-9585.
[http://dx.doi.org/10.3390/ijms22179579] [PMID: 34502483]

Ramadhani, D.; Maharani, R.; Gazzali, A.M.; Muchtaridi, M. Cyclic peptides for the treatment of cancers: A review. Molecules, 2022, 27(14), 4428.
[http://dx.doi.org/10.3390/molecules27144428] [PMID: 35889301]

Pinto, M.E.F.; Najas, J.Z.G.; Magalhães, L.G.; Bobey, A.F.; Mendonça, J.N.; Lopes, N.P.; Leme, F.M.; Teixeira, S.P.; Trovó, M.; Andricopulo, A.D.; Koehbach, J.; Gruber, C.W.; Cilli, E.M.; Bolzani, V.S. Inhibition of breast cancer cell migration by cyclotides isolated from pombalia calceolaria. J. Nat. Prod., 2018, 81(5), 1203-1208.
[http://dx.doi.org/10.1021/acs.jnatprod.7b00969] [PMID: 29757646]

Du, X.; Xiao, S.; Luo, Q.; Liu, X.; Liu, J. Laminaria japonica cyclic peptides exert anti-colorectal carcinoma effects through apoptosis induction in vitro and in vivo. J. Pept. Sci., 2022, 28(5), e3385-e3394.
[http://dx.doi.org/10.1002/psc.3385] [PMID: 34935253]

Li, D.; Liao, X.; Zhong, S.; Zhao, B.; Xu, S. Synthesis of marine cyclopeptide galaxamide analogues as potential anticancer agents. Mar. Drugs, 2022, 20(3), 158-169.
[http://dx.doi.org/10.3390/md20030158] [PMID: 35323457]

Suresh, K.; Abhishek, T.; Varsha, T.; Sukhbir Lal, K.; Renu, S.; Manish, K.; Ajay, S.; Tarun, V.; Reshu, V.; Girish, K.; Abdulsalam, A. Synthesis, anticancer, and antimicrobial evaluation of integerrimide-A. BioMed Res. Int., 2022.

S, R.; S, P.; Joann, M.D.; S, J. Evaluation of anti-inflammatory efficacy of RA-V: A natural cyclopeptide. Appl. Biochem. Biotechnol., 2020, 190(2), 732-744.
[http://dx.doi.org/10.1007/s12010-019-03124-9] [PMID: 31482289]

Liu, J.; Wang, H.; Wang, G.; Luo, Q.; Cao, H.; Liu, X.; Zhang, Z.; Yang, P.; Liu, Z. Anti-inflammatory potency of Locusta migratoria manilensis cyclopeptides in mast cells and macrophages. RSC Advances, 2019, 9(54), 31296-31305.
[http://dx.doi.org/10.1039/C9RA06284J] [PMID: 35527955]

Liu, J.; Gu, B.; Yang, L.; Yang, F.; Lin, H. New anti-inflammatory cyclopeptides from a sponge-derived fungus aspergillus violaceofuscus. Front Chem., 2018, 6, 226-233.
[http://dx.doi.org/10.3389/fchem.2018.00226] [PMID: 29963550]

(a) Alsaffar, R.M.; Ali, S.; Rashid, S.; Rashid, S.M.; Majid, S.; Rehman, M.U. Immunomodulation: An immune regulatory mechanism in carcinoma therapeutics. Int. Immunopharmacol., 2021, 99, 107984-107996.
[http://dx.doi.org/10.1016/j.intimp.2021.107984] [PMID: 34303999];
(b) Yang, Y.; Mao, H.; Chen, L.; Li, L. Targeting signal pathways triggered by cyclic peptides in cancer: Current trends and future challenges. Arch. Biochem. Biophys., 2021, 701, 108776-108790.
[http://dx.doi.org/10.1016/j.abb.2021.108776] [PMID: 33515532]

Chia, L.Y.; Kumar, P.V.; Maki, M.A.A.; Ravichandran, G.; Thilagar, S. A Review: The antiviral activity of cyclic peptides. Int. J. Pept. Res. Ther., 2022, 29(1), 7-33.
[http://dx.doi.org/10.1007/s10989-022-10478-y] [PMID: 36471676]

Park, J.Y.; Yang, S.Y.; Kim, Y.C.; Kim, J.C.; Dang, Q.L.; Kim, J.J.; Kim, I.S. Antiviral peptide from Pseudomonas chlororaphis O6 against tobacco mosaic virus (TMV). J. Korean Soc. Appl. Biol. Chem., 2012, 55(1), 89-94.
[http://dx.doi.org/10.1007/s13765-012-0015-2]

Song, X.; Lu, L.; Passioura, T.; Suga, H. Macrocyclic peptide inhibitors for the protein–protein interaction of Zaire Ebola virus protein 24 and karyopherin alpha 5. Org. Biomol. Chem., 2017, 15(24), 5155-5160.
[http://dx.doi.org/10.1039/C7OB00012J] [PMID: 28574091]

Lee, B.W.; Quy Ha, T.K.; Park, E.J.; Cho, H.M.; Ryu, B.; Doan, T.P.; Lee, H.J.; Oh, W.K. Melicopteline A–E, unusual cyclopeptide alkaloids with antiviral activity against influenza a virus from melicope pteleifolia. J. Org. Chem., 2021, 86(2), 1437-1447.
[http://dx.doi.org/10.1021/acs.joc.0c02137] [PMID: 33369410]

Johansen-Leete, J.; Ullrich, S.; Fry, S.E.; Frkic, R.; Bedding, M.J.; Aggarwal, A.; Ashhurst, A.S.; Ekanayake, K.B.; Mahawaththa, M.C.; Sasi, V.M.; Luedtke, S.; Ford, D.J.; O’Donoghue, A.J.; Passioura, T.; Larance, M.; Otting, G.; Turville, S.; Jackson, C.J.; Nitsche, C.; Payne, R.J. Antiviral cyclic peptides targeting the main protease of SARS-CoV-2. Chem. Sci., 2022, 13(13), 3826-3836.
[http://dx.doi.org/10.1039/D1SC06750H] [PMID: 35432913]

Smith, C.A.; Hinman, C.L. Evidence that L1AD3, an apoptosis-inducing cyclic peptide, binds a leukemic T-cell membrane protein receptor. Arch. Biochem. Biophys., 2004, 432(1), 88-101.
[http://dx.doi.org/10.1016/j.abb.2004.08.010] [PMID: 15519300]

Anderson, M.E.; Yakovleva, T.; Hu, Y.; Siahaan, T.J. Inhibition of ICAM-1/LFA-1-mediated heterotypic T-cell adhesion to epithelial cells: design of ICAM-1 cyclic peptides. Bioorg. Med. Chem. Lett., 2004, 14(6), 1399-1402.
[http://dx.doi.org/10.1016/j.bmcl.2003.09.100] [PMID: 15006370]

Chittasupho, C.; Manikwar, P.; Krise, J.P.; Siahaan, T.J.; Berkland, C. cIBR effectively targets nanoparticles to LFA-1 on acute lymphoblastic T cells. Mol. Pharm., 2010, 7(1), 146-155.
[http://dx.doi.org/10.1021/mp900185u] [PMID: 19883077]

Gründemann, C.; Thell, K.; Lengen, K.; Garcia-Käufer, M.; Huang, Y.H.; Huber, R.; Craik, D.J.; Schabbauer, G.; Gruber, C.W. Cyclotides suppress human T-lymphocyte proliferation by an interleukin 2-dependent mechanism. PLoS One, 2013, 8(6), e68016-e68027.
[http://dx.doi.org/10.1371/journal.pone.0068016] [PMID: 23840803]

Pinto, M.E.F.; Chan, L.Y.; Koehbach, J.; Devi, S.; Gründemann, C.; Gruber, C.W.; Gomes, M.; Bolzani, V.S.; Cilli, E.M.; Craik, D.J. Cyclotides from brazilian palicourea sessilis and their effects on human lymphocytes. J. Nat. Prod., 2021, 84(1), 81-90.
[http://dx.doi.org/10.1021/acs.jnatprod.0c01069] [PMID: 33397096]

Hazama, D.; Yin, Y.; Murata, Y.; Matsuda, M.; Okamoto, T.; Tanaka, D.; Terasaka, N.; Zhao, J.; Sakamoto, M.; Kakuchi, Y.; Saito, Y.; Kotani, T.; Nishimura, Y.; Nakagawa, A.; Suga, H.; Matozaki, T. Macrocyclic peptide-mediated blockade of the CD47-SIRPα interaction as a potential cancer immunotherapy. Cell Chem. Biol., 2020, 27(9), 1181-1191.e7.
[http://dx.doi.org/10.1016/j.chembiol.2020.06.008] [PMID: 32640189]

Karanam, G.; Arumugam, M.K.; Sirpu Natesh, N. Anticancer effect of marine sponge-associated Bacillus pumilus amk1 derived dipeptide cyclo (-Pro-Tyr) in human liver cancer cell line through apoptosis and G2/M phase arrest. Int. J. Pept. Res. Ther., 2020, 26(1), 445-457.
[http://dx.doi.org/10.1007/s10989-019-09850-2]

Karanam, G.; Arumugam, M.K. Reactive oxygen species generation and mitochondrial dysfunction for the initiation of apoptotic cell death in human hepatocellular carcinoma HepG2 cells by a cyclic dipeptide Cyclo(-Pro-Tyr). Mol. Biol. Rep., 2020, 47(5), 3347-3359.
[http://dx.doi.org/10.1007/s11033-020-05407-5] [PMID: 32248385]

Magiera-Mularz, K.; Kuska, K.; Skalniak, L.; Grudnik, P.; Musielak, B.; Plewka, J.; Kocik, J.; Stec, M.; Weglarczyk, K.; Sala, D.; Wladyka, B.; Siedlar, M.; Holak, T.A.; Dubin, G. Macrocyclic peptide inhibitor of PD-1/PD-L1 immune checkpoint. Adv. Ther., 2021, 4(2), 2000195-2000200.
[http://dx.doi.org/10.1002/adtp.202000195]

Zhai, W.; Zhou, X.; Zhai, M.; Li, W.; Ran, Y.; Sun, Y.; Du, J.; Zhao, W.; Xing, L.; Qi, Y.; Gao, Y. Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy. Sci. China Life Sci., 2021, 64(4), 548-562.
[http://dx.doi.org/10.1007/s11427-020-1740-8] [PMID: 32737851]

Zhai, W.; Zhou, X.; Wang, H.; Li, W.; Chen, G.; Sui, X.; Li, G.; Qi, Y.; Gao, Y. A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8⁺ T cell responses. Acta Pharm. Sin. B, 2020, 10(6), 1047-1060.
[http://dx.doi.org/10.1016/j.apsb.2020.01.005] [PMID: 32642411]

Miao, Q.; Zhang, W.; Zhang, K.; Li, H.; Zhu, J.; Jiang, S. Rational design of a potent macrocyclic peptide inhibitor targeting the PD-1/PD-L1 protein–protein interaction. RSC Advances, 2021, 11(38), 23270-23279.
[http://dx.doi.org/10.1039/D1RA03118J] [PMID: 35479790]

Wang, X.; Hu, C.; Wu, X.; Wang, S.; Zhang, A.; Chen, W.; Shen, Y.; Tan, R.; Wu, X.; Sun, Y.; Xu, Q.; Roseotoxin, B. Roseotoxin B improves allergic contact dermatitis through a unique anti-inflammatory mechanism involving excessive activation of autophagy in activated t lymphocytes. J. Invest. Dermatol., 2016, 136(8), 1636-1646.
[http://dx.doi.org/10.1016/j.jid.2016.04.017] [PMID: 27155460]

Shen, Y.; Luo, Q.; Xu, H.; Gong, F.; Zhou, X.; Sun, Y.; Wu, X.; Liu, W.; Zeng, G.; Tan, N.; Xu, Q. Mitochondria-dependent apoptosis of activated T lymphocytes induced by astin C, a plant cyclopeptide, for preventing murine experimental colitis. Biochem. Pharmacol., 2011, 82(3), 260-268.
[http://dx.doi.org/10.1016/j.bcp.2011.04.013] [PMID: 21569765]

Wang, Z.; Zhao, S.; Song, L.; Pu, Y.; Wang, Q.; Zeng, G.; Liu, X.; Bai, M.; Li, S.; Gao, F.; Chen, L.; Wang, C.; Tan, N. Natural cyclopeptide RA-V inhibits the NF-κB signaling pathway by targeting TAK1. Cell Death Dis., 2018, 9(7), 715.
[http://dx.doi.org/10.1038/s41419-018-0743-2] [PMID: 29915207]

Zou, X.G.; Shim, Y.Y.; Cho, J.Y.; Jeong, D.; Yang, J.; Deng, Z.Y.; Reaney, M.J.T. Flaxseed orbitides, linusorbs, inhibit LPS-induced THP-1 macrophage inflammation. RSC Advances, 2020, 10(38), 22622-22630.
[http://dx.doi.org/10.1039/C9RA09058D] [PMID: 35514549]

Matsoukas, J.M.; Ligielli, I.; Chasapis, C.T.; Kelaidonis, K.; Apostolopoulos, V.; Mavromoustakos, T. Novel approaches in the immunotherapy of multiple sclerosis: Cyclization of myelin epitope peptides and conjugation with mannan. Brain Sci., 2021, 11(12), 1583-1596.
[http://dx.doi.org/10.3390/brainsci11121583] [PMID: 34942885]

Hellinger, R.; Muratspahić, E.; Devi, S.; Koehbach, J.; Vasileva, M.; Harvey, P.J.; Craik, D.J.; Gründemann, C.; Gruber, C.W. Importance of the cyclic cystine knot structural motif for immunosuppressive effects of cyclotides. ACS Chem. Biol., 2021, 16(11), 2373-2386.
[http://dx.doi.org/10.1021/acschembio.1c00524] [PMID: 34592097]

Thell, K.; Hellinger, R.; Sahin, E.; Michenthaler, P.; Gold-Binder, M.; Haider, T.; Kuttke, M.; Liutkevičiūtė, Z.; Göransson, U.; Gründemann, C.; Schabbauer, G.; Gruber, C.W. Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis. Proc. Natl. Acad. Sci., 2016, 113(15), 3960-3965.
[http://dx.doi.org/10.1073/pnas.1519960113] [PMID: 27035952]

Dayani, L.; Dinani, M.S.; Aliomrani, M.; Hashempour, H.; Varshosaz, J.; Taheri, A. Immunomodulatory effects of cyclotides isolated from Viola odorata in an experimental autoimmune encephalomyelitis animal model of multiple sclerosis. Mult. Scler. Relat. Disord., 2022, 64, 103958-103972.
[http://dx.doi.org/10.1016/j.msard.2022.103958] [PMID: 35716476]

(a) Liddicoat, A.M.; Lavelle, E.C. Modulation of innate immunity by cyclosporine A. Biochem. Pharmacol., 2019, 163, 472-480.
[http://dx.doi.org/10.1016/j.bcp.2019.03.022] [PMID: 30880061];
(b) Patel, D.; Wairkar, S. Recent advances in cyclosporine drug delivery: challenges and opportunities. Drug Deliv. Transl. Res., 2019, 9(6), 1067-1081.
[http://dx.doi.org/10.1007/s13346-019-00650-1] [PMID: 31144214]

Fervenza, F.C.; Appel, G.B.; Barbour, S.J.; Rovin, B.H.; Lafayette, R.A.; Aslam, N.; Jefferson, J.A.; Gipson, P.E.; Rizk, D.V.; Sedor, J.R.; Simon, J.F.; McCarthy, E.T.; Brenchley, P.; Sethi, S.; Avila-Casado, C.; Beanlands, H.; Lieske, J.C.; Philibert, D.; Li, T.; Thomas, L.F.; Green, D.F.; Juncos, L.A.; Beara-Lasic, L.; Blumenthal, S.S.; Sussman, A.N.; Erickson, S.B.; Hladunewich, M.; Canetta, P.A.; Hebert, L.A.; Leung, N.; Radhakrishnan, J.; Reich, H.N.; Parikh, S.V.; Gipson, D.S.; Lee, D.K.; da Costa, B.R.; Jüni, P.; Cattran, D.C. Rituximab or cyclosporine in the treatment of membranous nephropathy. N. Engl. J. Med., 2019, 381(1), 36-46.
[http://dx.doi.org/10.1056/NEJMoa1814427] [PMID: 31269364]

Costa, L.; Sousa, E.; Fernandes, C. Cyclic peptides in pipeline: what future for these great molecules? Pharmaceuticals, 2023, 16(7), 996.
[http://dx.doi.org/10.3390/ph16070996] [PMID: 37513908]

Dhillon, S.; Keam, S.J. Bremelanotide: First approval. Drugs, 2019, 79(14), 1599-1606.
[http://dx.doi.org/10.1007/s40265-019-01187-w] [PMID: 31429064]

Scheinberg, A.R.; Martin, P.; Turkeltaub, J.A. Terlipressin in the management of liver disease. Expert Opin. Pharmacother., 2023, 24(15), 1665-1671.
[http://dx.doi.org/10.1080/14656566.2023.2244427] [PMID: 37535437]

Markham, A. Setmelanotide: First approval. Drugs, 2021, 81(3), 397-403.
[http://dx.doi.org/10.1007/s40265-021-01470-9] [PMID: 33638809]

Duggan, S. Vosoritide: First approval. Drugs, 2021, 81(17), 2057-2062.
[http://dx.doi.org/10.1007/s40265-021-01623-w] [PMID: 34694597]

Hoy, S.M. Pegcetacoplan: First approval. Drugs, 2021, 81(12), 1423-1430.
[http://dx.doi.org/10.1007/s40265-021-01560-8] [PMID: 34342834]

Heo, Y.A. Voclosporin: First approval. Drugs, 2021, 81(5), 605-610.
[http://dx.doi.org/10.1007/s40265-021-01488-z] [PMID: 33788181]

Keam, S.J. Lutetium Lu 177 vipivotide tetraxetan: First approval. Mol. Diagn. Ther., 2022, 26(4), 467-475.
[http://dx.doi.org/10.1007/s40291-022-00594-2] [PMID: 35553387]

Lamb, Y.N. Pacritinib: First approval. Drugs, 2022, 82(7), 831-838.
[http://dx.doi.org/10.1007/s40265-022-01718-y] [PMID: 35567653]

Syed, Y.Y. Rezafungin: First approval. Drugs, 2023, 83(9), 833-840.
[http://dx.doi.org/10.1007/s40265-023-01891-8] [PMID: 37212966]

Boivin-Jahns, V.; Uhland, K.; Holthoff, H.P.; Beyersdorf, N.; Kocoski, V.; Kerkau, T.; Münch, G.; Lohse, M.J.; Ungerer, M.; Jahns, R. Cyclopeptide COR-1 to treat beta1-adrenergic receptor antibody-induced heart failure. PLoS One, 2018, 13(8), e0201160.
[http://dx.doi.org/10.1371/journal.pone.0201160] [PMID: 30125285]

Anup, K.; Harri, J.; Raed Moh’d Taiseer, A-R.; Anwaar, S.; Milind, A.P.; Anusha, C.; Timothy, S.; Sean, K.; Mazin Mazin, A-K.; John, A.; Benjamin, M.; Samuel, L.; Mojtaba, O.; Amit, R.; Scott James, W.; Subhrajit, S.; Prasad, D.; Rashna, M.; Weijing, S.; Joaquina Celebre, B. Phase Ib/IIa trial of CEND-1 in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colorectal, and appendiceal cancers (CENDIFOX). J. Clin. Oncol., 2022, 40(16)

Mastellos, D.C.; Skendros, P.; Lambris, J.D. Is complement the culprit behind COVID-19 vaccine-related adverse reactions? J. Clin. Invest., 2021, 131(11), e151092.
[http://dx.doi.org/10.1172/JCI151092] [PMID: 33945504]

(a) Zhuang, L.; Huang, S.; Liu, W.Q.; Karim, A.S.; Jewett, M.C.; Li, J. Total in vitro biosynthesis of the nonribosomal macrolactone peptide valinomycin. Metab. Eng., 2020, 60, 37-44.
[http://dx.doi.org/10.1016/j.ymben.2020.03.009] [PMID: 32224263];
(b) Zhang, D.; Ma, Z.; Chen, H.; Lu, Y.; Chen, X. Valinomycin as a potential antiviral agent against coronaviruses: A review. Biomed. J., 2020, 43(5), 414-423.
[http://dx.doi.org/10.1016/j.bj.2020.08.006] [PMID: 33012699]

O’Shaughnessy, J.; Kaklamani, V.; Kalinsky, K. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer. Future Oncol., 2019, 15(14), 1641-1653.
[http://dx.doi.org/10.2217/fon-2018-0936] [PMID: 30892083]

Barth, P.; Bruijnzeel, P.; Wach, A.; Sellier Kessler, O.; Hooftman, L.; Zimmermann, J.; Naue, N.; Huber, B.; Heimbeck, I.; Kappeler, D.; Timmer, W.; Chevalier, E. Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis. J. Cyst. Fibros., 2020, 19(2), 299-304.
[http://dx.doi.org/10.1016/j.jcf.2019.08.020] [PMID: 31501052]

Guerlavais, V.; Sawyer, T.K.; Carvajal, L.; Chang, Y.S.; Graves, B.; Ren, J.G.; Sutton, D.; Olson, K.A.; Packman, K.; Darlak, K.; Elkin, C.; Feyfant, E.; Kesavan, K.; Gangurde, P.; Vassilev, L.T.; Nash, H.M.; Vukovic, V.; Aivado, M.; Annis, D.A. Discovery of sulanemadlin (ALRN-6924), the first cell-permeating, stabilized α-helical peptide in clinical development. J. Med. Chem., 2023, 66(14), 9401-9417.
[http://dx.doi.org/10.1021/acs.jmedchem.3c00623] [PMID: 37439511]

Howard, J.F., Jr; Bresch, S.; Genge, A.; Hewamadduma, C.; Hinton, J.; Hussain, Y.; Juntas-Morales, R.; Kaminski, H.J.; Maniaol, A.; Mantegazza, R.; Masuda, M.; Sivakumar, K.; Śmiłowski, M.; Utsugisawa, K.; Vu, T.; Weiss, M.D.; Zajda, M.; Boroojerdi, B.; Brock, M.; de la Borderie, G.; Duda, P.W.; Lowcock, R.; Vanderkelen, M.; Leite, M.I.; Sembinelli, D.; Teitelbaum, J.; Nicolle, M.; Bernard, E.; Svahn, J.; Spinazzi, M.; Stojkovic, T.; Demeret, S.; Weiss, N.; Le Guennec, L.; Messai, S.; Tranchant, C.; Nadaj-Pakleza, A.; Chanson, J-B.; Suliman, M.; Zaidi, L.; Tard, C.; Lecointe, P.; Zschüntzsch, J.; Schmidt, J.; Glaubitz, S.; Zeng, R.; Scholl, M.; Kowarik, M.; Ziemann, U.; Krumbholz, M.; Martin, P.; Ruschil, C.; Dünschede, J.; Kemmner, R.; Rumpel, N.; Berger, B.; Totzeck, A.; Hagenacker, T.; Stolte, B.; Iorio, R.; Evoli, A.; Falso, S.; Antozzi, C.; Frangiamore, R.; Vanoli, F.; Rinaldi, E.; Deguchi, K.; Minami, N.; Nagane, Y.; Suzuki, Y.; Ishida, S.; Suzuki, S.; Nakahara, J.; Nagaoka, A.; Yoshimura, S.; Konno, S.; Tsuya, Y.; Uzawa, A.; Kubota, T.; Takahashi, M.; Okuno, T.; Murai, H.; Gilhus, N.E.; Boldingh, M.; Rønning, T.H.; Chyrchel-Paszkiewicz, U.; Kumor, K.; Zielinski, T.; Banaszkiewicz, K.; Błaż, M.; Kłósek, A.; Świderek-Matysiak, M.; Szczudlik, A.; Paśko, A.; Szczechowski, L.; Banach, M.; Ilkowski, J.; Kapetanovic Garcia, S.; Ortiz Bagan, P.; Belén Cánovas Segura, A.; Turon Sans, J.; Vidal Fernandez, N.; Cortes Vicente, E.; Rodrigo Armenteros, P.; Ashraghi, M.; Cavey, A.; Haslam, L.; Emery, A.; Liow, K.; Yegiaian, S.; Barboi, A.; Vazquez, R.M.; Lennon, J.; Pascuzzi, R.M.; Bodkin, C.; Guingrich, S.; Comer, A.; Bromberg, M.; Janecki, T.; Saba, S.; Tellez, M.; Elsheikh, B.; Freimer, M.; Heintzman, S.; Govindarajan, R.; Guptill, J.; Massey, J.M.; Juel, V.; Gonzalez, N.; Habib, A.A.; Mozaffar, T.; Korb, M.; Goyal, N.; Machemehl, H.; Manousakis, G.; Allen, J.; Harper, E.; Farmakidis, C.; Saavedra, L.; Dimachkie, M.; Pasnoor, M.; Akhter, S.; Beydoun, S.; McIlduff, C.; Nye, J.; Roy, B.; Munro Sheldon, B.; Nowak, R.; Barnes, B.; Rivner, M.; Suresh, N.; Shaw, J.; Harvey, B.; Lam, L.; Thomas, N.; Chopra, M.; Traub, R.E.; Jones, S.; Wagoner, M.; Smajic, S.; Aly, R.; Katz, J.; Chen, H.; Miller, R.G.; Jenkins, L.; Khan, S.; Khatri, B.; Sershon, L.; Pavlakis, P.; Holzberg, S.; Li, Y.; Caristo, I.B.; Marquardt, R.; Hastings, D.; Rube, J.; Lisak, R.P.; Choudhury, A.; Ruzhansky, K.; Sachdev, A.; Shin, S.; Bratton, J.; Fetter, M.; McKinnon, N.; McKinnon, J.; Sissons-Ross, L.; Sahu, A.; Distad, B.J. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): A randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol., 2023, 22(5), 395-406.
[http://dx.doi.org/10.1016/S1474-4422(23)00080-7] [PMID: 37059508]

Mammen, A.L.; Amato, A.A.; Dimachkie, M.M.; Chinoy, H.; Hussain, Y.; Lilleker, J.B.; Pinal-Fernandez, I.; Allenbach, Y.; Boroojerdi, B.; Vanderkelen, M.; Delicha, E.M.; Koendgen, H.; Farzaneh-Far, R.; Duda, P.W.; Sayegh, C.; Benveniste, O.; Amato, A.A.; Benveniste, O.; Biliciler, S.; Chinoy, H.; Dimachkie, M.M.; Edmundson, C.; Freimer, M.; Geraci, A.; Hussain, Y.; Machado, P.; Mammen, A.L.; Mozaffar, T.; Soltanzadeh, P.; Suresh, N.; van der Kooi, A.; Allenbach, Y.; Appleby, M.; Barohn, R.J.; Champtiaux, N.; Doughty, C.; Farias, J.; Farmakidis, C.; Habib, A.A.; Karam, C.; Lilleker, J.; Lorusso, S.; Pasnoor, M.; Pinal-Fernandez, I.; Querin, G.; Raaphorst, J.; Ransley, G.; Saba, S.; Sheikh, K.; Snedden, A.; Statland, J.; Vu, T. Zilucoplan in immune-mediated necrotising myopathy: A phase 2, randomised, double-blind, placebo-controlled, multicentre trial. Lancet Rheumatol., 2023, 5(2), e67-e76.
[http://dx.doi.org/10.1016/S2665-9913(23)00003-6] [PMID: 36923454]

Cook, N.; Banerji, U.; Evans, J.; Biondo, A.; Germetaki, T.; Randhawa, M.; Godfrey, L.; Leslie, S.; Jeffrey, P.; Rigby, M.; Bennett, G.; Blakemore, S.; Koehler, M.; Niewiarowski, A.; Pittman, M.; Symeonides, S.N. 464PPharmacokinetic (PK) assessment of BT1718: A phase I/II a study of BT1718, a first in class bicycle toxin conjugate (BTC), in patients (pts) with advanced solid tumours. Ann. Oncol., 2019, 30(5)

Capucine, B.; Vincent, G.; Irene, B.; Bernard, D.; Antoine, I.; Sophie, C.; Gerald Steven, F.; Andrea, N.; Oscar, R.; Louise, C.; Elisa, F.; Loic, V.; Sebastien, H.; Amy, D.; Cong, X.; Hongmei, X.; Rajiv, S.; Dominic, S.; Meredith, M. BT8009-100: A phase I/II study of novel bicyclic peptide and MMAE conjugate BT8009 in patients (pts) with advanced malignancies associated with nectin-4 expression, including urothelial cancer (UC). J. Clin. Oncol., 2023, 41(6), 498-498.

Bendell, J.C.; Wang, J.S.Z.; Bashir, B.; Richardson, D.L.; Bennett, G.; Campbell, C.; Hennessy, M.G.; Jeffrey, P.; Kirui, J.; Mahnke, L.; Shapiro, G. BT5528-100 phase I/II study of the safety, pharmacokinetics, and preliminary clinical activity of BT5528 in patients with advanced malignancies associated with EphA2 expression. J. Clin. Oncol., 2020, 38(15_suppl), TPS3655.
[http://dx.doi.org/10.1200/JCO.2020.38.15_suppl.TPS3655]

Kyriakos, P.P.; Afshin, D.; Amy, D.; Sandra, H.; Sally, W.; Punit, U.; Heather, C.; Kristen, H.; Roshawn, W.; Sebastien, H.; Dominic, S.; Jordi Rodon, A. A combined phase I/II study of a novel bicycle tumor-targeted immune cell agonist BT7480 in patients with nectin-4 associated advanced malignancies. J. Clin. Oncol., 2022, 40(16)

Wyer, S.; Townsend, D.M.; Ye, Z.; Kourtidis, A.; Choo, Y.M.; de Barros, A.L.B.; Donia, M.S.; Hamann, M.T. Recent advances and limitations in the application of kahalalides for the control of cancer. Biomed. Pharmacother., 2022, 148, 112676-112685.
[http://dx.doi.org/10.1016/j.biopha.2022.112676] [PMID: 35149387]

a) Ling, Y.H.; Aracil, M.; Zou, Y.; Yuan, Z.; Lu, B.; Jimeno, J.; Cuervo, A.M.; Perez-Soler, R. PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of death-associated protein kinase. Clin. Cancer Res., 2011, 17(16), 5353-5366.
[http://dx.doi.org/10.1158/1078-0432.CCR-10-1948] [PMID: 21690574];
b) Martín-Algarra, S.; Espinosa, E.; Rubió, J.; López, J.J.L.; Manzano, J.L.; Carrión, L.A.; Plazaola, A.; Tanovic, A.; Paz-Ares, L. Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma. Eur. J. Cancer, 2009, 45(5), 732-735.
[http://dx.doi.org/10.1016/j.ejca.2008.12.005] [PMID: 19186051]

Ballantyne, C.M.; Banka, P.; Mendez, G.; Garcia, R.; Rosenstock, J.; Rodgers, A.; Mendizabal, G.; Mitchel, Y.; Catapano, A.L. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. J. Am. Coll. Cardiol., 2023, 81(16), 1553-1564.
[http://dx.doi.org/10.1016/j.jacc.2023.02.018] [PMID: 36889610]

Tanada, M.; Tamiya, M.; Matsuo, A.; Chiyoda, A.; Takano, K.; Ito, T.; Irie, M.; Kotake, T.; Takeyama, R.; Kawada, H.; Hayashi, R.; Ishikawa, S.; Nomura, K.; Furuichi, N.; Morita, Y.; Kage, M.; Hashimoto, S.; Nii, K.; Sase, H.; Ohara, K.; Ohta, A.; Kuramoto, S.; Nishimura, Y.; Iikura, H.; Shiraishi, T. Development of orally bioavailable peptides targeting an intracellular protein: From a hit to a clinical KRAs inhibitor. J. Am. Chem. Soc., 2023, 145(30), 16610-16620.
[http://dx.doi.org/10.1021/jacs.3c03886] [PMID: 37463267]

Saharan, R.; Kumar, S.; Khokra, S.L. A comprehensive review on therapeutic potentials of natural cyclic peptides. Curr. Nutr. Food Sci., 2021, 18, 441-449.